For decades, the medical and life science communities have discussed boosting diversity in clinical trials. However, research today is still coming up short. According to a 2019 JAMA study, out of 230 trials leading to FDA oncology drug approvals over the past decade, race was only reported by 63%.
“We would want representation of trial participants to reflect the population of the disease that'...
The first technology-enabled remote clinical trial was launched nearly a decade ago, and that field – now generally referred to as "decentralized clinical trials" – has been advancing and gaining traction ever since. But, like so many other remote tools, it's been greatly accelerated by the COVID-19 pandemic.
On today's HIMSSCast, host Jonah Comstock and MobiHealthNews Managing Editor Laura...
Clinical trials have become big news this year amid the search for COVID-19 vaccines and treatments. They are a critical component of helping the FDA validate that new drugs and diagnostics will be both safe and effective.
Pharmaceutical companies spend over $45B a year running clinical trials, which are, by design, very methodical and measured. Unfortunately, they are also slow, unpredictable...
Oxford-based biotech company, Theolytics has announced the closing of a US $6.8 million (£5 million) Series A round.
The round was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing investor, Oxford Sciences Innovation (OSI).
The financing will be used to progress the company’s pipeline of candidates towards human clinical trials.
WHY IT MATTERS
Theolytics will...
A new platform aimed at streamlining clinical trials in order to lower costs – and increase the efficiency and success rate of a drug or the development of a medical device – has been unveiled by Ben-Gurion University of the Negev (BGU).
The yet-to-be-named programme reportedly “leverages machine learning to optimise a clinical trial’s chances of success” through the analysis of factors including...
UK-based independent SMO, Panthera Biopartners has completed a Series A funding round with Gresham House Ventures as a major investor.
WHY IT MATTERS
Panthera is looking to extend its UK site network by opening a new clinic in Glasgow and expanding existing locations to service higher patient volumes and take forward alliance partnerships across Europe.
The Series A funding will also ensure...
UK-based data capture software company, uMotif, has raised £5 million in a Series A investment round led by existing investor AlbionVC.
The funding will accelerate uMotif’s growth and enable further development of its patient-centric and decentralised approach to clinical studies and enable expansion into new study types and more high-demand territories.
WHY IT MATTERS
Life sciences companies...
Historically, women have been underrepresented in clinical trials, however, that paradigm is changing. This shift is mainly due to policy changes in the last three decades, but today many innovators are also seeing a role for tech to play in closing this gap.
This morning MobiHealthNews sat down with a panel at Women of Wearables’ FemTech Forum to moderate a discussion about the gender gap in...
The FDA and National Institutes of Health are tapping the clinical community and a newly launched mobile platform in its search for novel infectious disease interventions.
Called CURE ID, the online data repository will allow clinicians to report instances in which existing FDA-approved drugs are used to successfully treat infections.
In particular, the tool captures clinical outcomes in cases...
Atlanta-based Florence Healthcare, a maker of software for clinical trials, has raised $7.1 million in a Series B funding round led by Fulcrum Equity Partners, with additional participation from Atrium Health and Bee Partners.
The round brings the company's total funding to at least $8.8 million, with a $1.7 million seed round from 2016.
WHAT THEY DO
Not to be confused with the UK social care...
.jpg?itok=fshRV9W- "The company will expand its oncolytic viral therapy platform to combat cancer.")
.jpg?itok=MZ_RxCEv "The yet-to-be-named programme reportedly “leverages machine learning to optimise a clinical trial’s chances of success” through the analysis of factors such as patient population recruitment and dropout rate.")
